On December 13, 2022 RemedyBio, an immune therapy discovery and development biotech company, combining the power of functional immune mapping through its proprietary Nanoreactor platform for the discovery of new immune oncology therapies, reported a research and evaluation agreement with Glaxo Smith Kline (GSK) to identify and analyse certain rare immune cells and their function within tumours (Press release, Remedy Biologics, DEC 13, 2022, View Source [SID1234644120]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The outputs from this evaluation may allow GSK to address certain biological questions that are difficult or impossible to answer via other methods.

"We are excited to collaborate closely with the immune oncology team at GSK.", said Dan Crowley, CEO and co-founder of RemedyBio. "Our work in immune cell function, with the scale and speed offered by our unique platform, has allowed us to decipher and understand the complexities associated with rare cell to cell interactions in the TME and tumour, directly exploring complex scientific questions in this GSK collaboration."

In addition to its collaborations with Pharma and oncology focussed institutions, RemedyBio continues to develop its own pipeline in the immune oncology space, through functional discovery of therapies directly from patient biology.